Skip to main content Help with accessibility Skip to main navigation

Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, biological agents in the management of

Last Updated: 31 January 2018

Body System: Musculoskeletal system

Red
Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, biological agents in the management of

The Pan Mersey Area Prescribing Committee recommends the use of adalimumab, certolizumab pegol, etanercept, golimumab, infliximab and secukinumabâ–¼ in the management of ankylosing spondylitis (AS), and adalimumab, certolizumab pegol, golimumab and etanercept in non-radiographic axial spondyloarthritis (NRAxSpA) in accordance with NICE TA383, NICE TA407 and NICE TA497.

Prescribing pathway